Implantica's Capital Markets Day Scheduled for September 9 in Stockholm

Implantica to Host Capital Markets Day in Stockholm

Implantica AG, a cutting-edge medtech company, is gearing up for its much-anticipated Capital Markets Day, taking place on September 9, 2026, from 14:00 to 16:30 CEST in the heart of Stockholm. This event promises to be a significant milestone for both the company and its stakeholders as it aims to shed light on the future trajectory of its flagship product, RefluxStop®. With a growing number of Americans suffering from gastroesophageal reflux disease (GERD), estimated at 78 million, the implications of this event are wide-reaching.

What to Expect from the Event

The Capital Markets Day will be hosted at Sergelkonferensen, located at Mäster Samuelsgatan 42, Stockholm. Attendees will be treated to insights from Implantica's management team alongside various surgeons who specialize in the RefluxStop® procedure. Moreover, firsthand perspectives from patients who have benefited from this innovative treatment will also be highlighted, offering a rounded view of the impact of RefluxStop® in clinical practice.

One of the key focuses of the day will be Implantica’s strategic plans following the recent FDA approval of RefluxStop®. As the company sets its sights on launching in the U.S. market, management will outline the comprehensive roadmap that aims to capitalize on this significant growth opportunity. With patient outcomes and clinical effectiveness taking center stage, stakeholders will gain a clearer understanding of the product’s potential to transform the current standard of care in anti-reflux surgery.

Why RefluxStop® Is a Game-Changer

RefluxStop® has been lauded as a pioneering solution for GERD, addressing the root cause rather than merely the symptoms. Traditional anti-reflux surgeries often lead to uncomfortable side effects, including difficulty swallowing and gas bloating. In contrast, the RefluxStop® procedure is designed to restore the lower esophageal sphincter's natural function, eliminating reflux without wrapping or constricting the esophagus. This innovative approach is intended to minimize the adverse effects seen in other surgical options and provides a solution for patients seeking long-term relief.

As part of the event, management will also delve into the company’s plans for future products and technologies, including an eHealth platform for remote monitoring of implants and a wireless energy platform that promises to keep medical devices powered without invasive procedures.

Join the Conversation

For those unable to attend in person, participants can join via live webcast, ensuring that no one misses out on these critical discussions. Interested parties can register through the Implantica website or directly via the provided links. This level of accessibility demonstrates Implantica's commitment to transparency and engagement with its stakeholders and the broader medical community.

As the medical landscape evolves, Implantica's Capital Markets Day serves as a critical juncture for anyone eager to understand the future of GERD treatment and the role of innovative technology in enhancing patient quality of life. With clinical outcomes already published in peer-reviewed journals, the event promises insights backed by solid data and real-world results.

If you want to follow the proceedings live, access the link to the webcast and be part of this significant occasion. For more details or specific inquiries, interested individuals can reach out to Nicole Pehrsson, Chief Corporate Affairs Officer, or contact the company directly for assistance.

Implantica's stock is traded on the Nasdaq First North Premier Growth Market, underscoring its status as a forward-thinking player in the medtech space. As they unveil their plans in Stockholm, all eyes will be on how they aim to redefine treatment standards and improve lives through their innovative healthcare solutions.